Clinical factors and comorbidities affecting the cost of hospital-treated COPD

Basit Öğe Kaydı
dc.contributor.authorDeniz, Sami
dc.contributor.authorSengul, Aysun
dc.contributor.authorAydemir, Yusuf
dc.contributor.authorEmre, Julide Celdir
dc.contributor.authorOzhan, Mustafa Hikmet
dc.date.accessioned2019-10-27T22:57:44Z
dc.date.available2019-10-27T22:57:44Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: We aimed to assess the effects of comorbidities on COPD costs and to investigate the relationship between comorbidities and clinical variables. Patients and methods: All patients hospitalized with a diagnosis of COPD exacerbation between January 1, 2014, and December 31, 2014, at all state hospitals of Aydin province, a city located in the western part of Turkey, were included in this study. The costs examined in the study pertained to medications, laboratory tests, hospital stays, and other treatment-related factors, such as consumption of materials, doctor visits, and consultation fees. Results: A total of 3,095 patients with 5,237 exacerbations (mean age, 71.9+/-10.5 years; 2,434 males and 661 females) were evaluated. For 880 of the patients (28.9%), or 3,852 of the exacerbations (73.1%), at least one comorbid disease was recorded. The mean cost of each exacerbation was $808.5+/-1,586, including $325.1+/-879.9 (40.7%) for hospital stays, $223.1+/-1,300.9 (27.6%) for medications, $46.3+/-49.6 (0.9%) for laboratory expenditures, and $214+/-1,068 (26.5%) for other treatment-related factors, such as consumption of materials, doctor visits, and consultation fees. The cost of each exacerbation was $1,014.9 in patients with at least one comorbidity, whereas it was $233.6 in patients without comorbidity (P<0.001). Age >65 years, female gender, hospitalization in an intensive care unit, invasive or noninvasive mechanical ventilation, and a long duration of hospitalization were all found to be significant factors in increasing total costs during the exacerbations requiring hospitalization (P<0.05 for all). Conclusion: Comorbidities have an important role in the total costs of acute exacerbations of COPD. Strategies for the prevention, diagnosis, and effective management of comorbidities would decrease the overall financial burden associated with acute exacerbations of COPD.en_US
dc.identifier.doi10.2147/COPD.S120637en_US
dc.identifier.endpage3030en_US
dc.identifier.issn1178-2005
dc.identifier.pmid27980399en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3023en_US
dc.identifier.urihttps://doi.org/10.2147/COPD.S120637
dc.identifier.urihttps://hdl.handle.net/11454/51307
dc.identifier.volume11en_US
dc.identifier.wosWOS:000389085400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofInternational Journal of Chronic Obstructive Pulmonary Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOPDen_US
dc.subjectexacerbationen_US
dc.subjectcosten_US
dc.subjectcomorbidityen_US
dc.subjectmorbidityen_US
dc.subjectintensive care uniten_US
dc.titleClinical factors and comorbidities affecting the cost of hospital-treated COPDen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu